Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1129-2377
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months ; volume:22 ; number:1 ; day:7 ; month:10 ; year:2021 ; pages:1-7 ; date:12.2021
The journal of headache and pain ; 22, Heft 1 (7.10.2021), 1-7, 12.2021
- Creator
-
Caronna, Edoardo
Gallardo, Victor José
Alpuente, Alicia
Torres-Ferrus, Marta
Pozo-Rosich, Patricia
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s10194-021-01328-1
- URN
-
urn:nbn:de:101:1-2021122420452478731711
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:20 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Caronna, Edoardo
- Gallardo, Victor José
- Alpuente, Alicia
- Torres-Ferrus, Marta
- Pozo-Rosich, Patricia
- SpringerLink (Online service)
Other Objects (12)
CGRP-monoclonal antibodies in difficult-to-treat chronic migraine patients
Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention?
“Triaging” Chronic Migraine Patients in Need of CGRP(r) Monoclonal Antibodies
Persistent effectiveness of CGRP antibody therapy in migraine and comorbid medication overuse or medication overuse headache - a retrospective real-world analysis
Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review
Interictal burden in migraine patients at the outset of CGRP monoclonal antibody prevention
Why are CGRP monoclonal antibodies not yet the first line treatment in migraine prevention?
CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs
It is time anti-CGRP monoclonal antibodies be considered first-line prophylaxis for migraine
CGRP and migraine: neurogenic inflammation revisited
Monoclonal Antibodies Targeting CGRP to Treat Vestibular Migraine: A Rapid Systematic Review and Meta-Analysis
Role of CGRP pathway polymorphisms in migraine: a systematic review and impact on CGRP mAbs migraine therapy
CGRP-monoclonal antibodies in difficult-to-treat chronic migraine patients
Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention?
“Triaging” Chronic Migraine Patients in Need of CGRP(r) Monoclonal Antibodies
Persistent effectiveness of CGRP antibody therapy in migraine and comorbid medication overuse or medication overuse headache - a retrospective real-world analysis
Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review
Interictal burden in migraine patients at the outset of CGRP monoclonal antibody prevention
Why are CGRP monoclonal antibodies not yet the first line treatment in migraine prevention?
CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs
It is time anti-CGRP monoclonal antibodies be considered first-line prophylaxis for migraine
CGRP and migraine: neurogenic inflammation revisited
Monoclonal Antibodies Targeting CGRP to Treat Vestibular Migraine: A Rapid Systematic Review and Meta-Analysis
Role of CGRP pathway polymorphisms in migraine: a systematic review and impact on CGRP mAbs migraine therapy
CGRP-monoclonal antibodies in difficult-to-treat chronic migraine patients
Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention?
“Triaging” Chronic Migraine Patients in Need of CGRP(r) Monoclonal Antibodies
Persistent effectiveness of CGRP antibody therapy in migraine and comorbid medication overuse or medication overuse headache - a retrospective real-world analysis
Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review
Interictal burden in migraine patients at the outset of CGRP monoclonal antibody prevention
Why are CGRP monoclonal antibodies not yet the first line treatment in migraine prevention?
CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs
It is time anti-CGRP monoclonal antibodies be considered first-line prophylaxis for migraine
CGRP and migraine: neurogenic inflammation revisited
Monoclonal Antibodies Targeting CGRP to Treat Vestibular Migraine: A Rapid Systematic Review and Meta-Analysis